Objective: Many patients have complicated recoveries following severe trauma due to the development of organ injury. Physiological and anatomical prognosticators have had limited success in predicting clinical trajectories. We report on the development and retrospective validation of a simple genomic composite score that can be rapidly used to predict clinical outcomes. Design: Retrospective cohort study. Setting: Multi-institutional level 1 trauma centers.
Objective: Many patients have complicated recoveries following severe trauma due to the development of organ injury. Physiological and anatomical prognosticators have had limited success in predicting clinical trajectories. We report on the development and retrospective validation of a simple genomic composite score that can be rapidly used to predict clinical outcomes. Design: Retrospective cohort study. Setting: Multi-institutional level 1 trauma centers.
Patients: Data were collected from 167 severely traumatized (injury severity score >15) adult (18-55 yr) patients. Methods: Microarray-derived genomic data obtained from 167 severely traumatized patients over 28 days were assessed for differences in messenger RNA abundance among individuals with different clinical trajectories. Once a set of genes was identified based on differences in expression over the entire study period, messenger RNA abundance from these subjects obtained in the first 24 hours was analyzed in a blinded fashion using a rapid multiplex platform, and genomic data reduced to a single metric. Results: From the existing genomic dataset, we identified 63 genes whose leukocyte expression differed between an uncomplicated and complicated clinical outcome over 28 days. Using a multiplex approach that can quantitate messenger RNA abundance in less than 12 hours, we reassessed total messenger RNA abundance from the first 24 hours after trauma and reduced the genomic data to a single composite score using the difference from reference. This composite score showed good discriminatory capacity to distinguish patients with a complicated outcome (area under a receiver-operator curve, 0.811; p <0.001). This was significantly better than the predictive power of either Acute Physiology and Chronic Health Evaluation II or new injury severity score scoring systems. Conclusions: A rapid genomic composite score obtained in the first 24 hours after trauma can retrospectively identify trauma patients who are likely to develop complicated clinical trajectories. A novel platform is described in which this genomic score can be obtained within 12 T raumatic injury remains the most common cause of death in individuals younger than 45 years old and is a significant healthcare burden (1, 2) . Although risk factors such as increasing age, number of premorbid conditions, and injury severity are well-known causes of increased mortality following traumatic injury (3, 4) , predictive models based on physiologic and clinical parameters still lack the specificity and sensitivity to identify individual patients at risk of developing organ injury or sepsis.
Current evidence suggests that a systemic immunological dysregulation is central to the organ injury following trauma. While our understanding of the systemic consequences of severe injury and sepsis remains incomplete, as evidenced by the lack of success in translational and clinical trials of therapies aimed at modulating the inflammatory response (5, 6) , the development of prognosticators based on immunological measures are plentiful (7) (8) (9) (10) (11) (12) . Unfortunately, these diagnostics and prognostics have not proved sufficiently successful to enter the clinical armamentarium.
To obtain a better global understanding of the complex immune response following severe injury in humans, we examined genome-wide expression patterns of blood leukocytes following severe injury, and observed what was termed a "genomic storm," in which greater than 75% of the host leukocyte transcriptome was altered following severe injury (13) . More importantly, we demonstrated that genomic information collected in the first 12 hours of severe trauma contained information independent of anatomical and physiological prognosticators that was associated with different clinical outcomes (14) . In a more recent study, we further demonstrated that differences in leukocyte genomic information obtained over the first 4 days was associated with patients who would die from organ failure or would have prolonged complicated courses (15) . Such findings strongly suggest that genomic information contained in whole blood leukocytes in the immediate posttrauma period could be used to develop a prognostic tool to determine outcome and, theoretically, identify those patients most likely to benefit from interventions.
In this report, we propose a novel platform to conduct genomic measurements from whole blood leukocytes to identify severely traumatized patients who will have a complicated clinical recovery. Using existing microarray data from the Glue-Grant (GG) collaborative research program (Inflammation and the Host Response to Injury), we identified 63 genes from 167 severely injured patients whose leukocyte gene expression differs among patients with different clinical outcomes over 28 days. Using existing RNA samples from the collaborative research program obtained in the first 24 hours after trauma, we then conducted a proof of principle study to retrospectively validate the microarray data using a multiplex RNA quantification scheme based on fluorescently labeled codesets that can quantitate the 63 gene expression levels simultaneously within 12 hours of sample collection (NanoString nCounter Gene Analysis, NanoString Technologies, Seattle, WA). The gene expression data were reevaluated in all 167 subjects, and the resulting gene expression data were reduced to a single metric, as described previously (14) .
Based on the findings reported here, we propose that such a genomic score can feasibly be utilized as a prognostic tool in the clinical setting to identify trauma patients at risk of developing organ injury and adverse outcomes, to guide clinical decisions regarding treatment.
METHODS

Subject Recruitment and Affymetrix U133 GeneChip Data Analysis
One hundred sixty-seven patients between the ages of 18 and 55 who suffered severe blunt injury were enrolled from six institutions between November 2003 and January 2005 and compared with 35 age-and gender-matched healthy control subjects (13) . Samples were collected with signed informed consent; each institution had its own institutional review board approval, and de identified clinical data are now in the public domain (16) . Blood samples were collected within 12 hours of injury and at 1, 4, 7, 14, 21, and 28 days after the injury while hospitalized in the ICU, whole blood nucleated cells were isolated, and genome-wide expression analyses of 54,675 probe sets were performed using the Affymetrix U133 GeneChip (Affymetrix, Santa Clara, CA) (17, 18) .
Statistical analysis to assess the overall gene expression patterns following trauma was performed (13) . Briefly, trauma patients were divided into three cohorts based on their clinical trajectory being either "uncomplicated" (as defined by the absence or resolution of organ injury; modified Marshall Multiple Organ Failure Score) in <5 days), "complicated" (resolution of organ injury in >14 days or no recovery by 28 days, or death), or " intermediate. " We focused our initial analyses on the extremes of outcome: those patients who had either a complicated trajectory or an uncomplicated clinical course. Using the EDGE software program (http://www.genomine.org/edge/), statistical analysis was performed to assess differences in gene expression over the entire 28-day sampling period between complicated and uncomplicated patients (19, 20) . Using this approach, we were able to identify a set of genes that were differentially expressed using a false discovery rate-adjusted probability of less than 0.001. We then filtered that set to include only the genes that had at least a twofold maximal difference in expression between the two clinical trajectories, which resulted in a set of 63 genes. Gene expression data from those 63 genes were reduced to a single metric that was then independently tested for its predictive ability at a single clinically relevant time point, 24 hours, that evaluated the magnitude of the difference in expression from healthy, control subjects using a statistical tool that reduces multiplex genomic data to a single metric difference from reference (DFR) (14) . The DFR calculates the sum of the normalized differences in expression for each of the genes from the mean expression obtained from age-, gender-, and ethnicity-matched controls, using the following equation (14):
where e i is the patient's expression level and M i and V i are the control group mean and variance for the ith probe set. Division by the control variance is a rescaling that prevents the DFR score from being dominated by genes that are inherently more variable or more highly expressed. The natural logarithm is applied to make the distribution of the resulting DFR more symmetric over the patient population (14) . In essence, DFR calculates the distance between each patient's gene expression profile and the profile obtained from the healthy reference subjects.
Validation of Affymetrix U133 GeneChip Analysis With NanoString nCounter Gene Expression Analysis
A custom-made NanoString nCounter codeset was used to perform a quantitative analysis that could retrospectively validate the Affymetrix U133 GeneChip microarray analysis, and included only the 63 genes that were found to be differentially expressed between complicated and uncomplicated patients, and seven variably expressed housekeeping genes. In order to assess the analytical variance of the NanoString platform to detect small differences in array expression, we performed an ex vivo study using a human whole blood sample that was stimulated with lipopolysaccharide (Escherichia coli O26:B6, 100 ng/mL) for 2 hours a 37°C and compared with unstimulated samples. One healthy, human subject provided signed informed consent, and the protocol had been approved by the University of Florida Institutional Review Board. The sample was divided into 10 aliquots, and five were stimulated with lipopolysaccharide (LPS); five were unstimulated and processed immediately. RNA was isolated using identical protocols to those employed for the clinical samples (15, 18) , and five replicates from both LPS-stimulated and unstimulated blood were analyzed using both the Affymetrix U133 + v2 GeneChip and the NanoString technology. The NanoString technology employs two sequence-specific complimentary probes with a unique code for each of the genes of interest (21) . Probe pairs containing a reporter probe with a signal on its 5' end, and a capture probe with biotin on the 3' end with an individualized fluorescent barcode were hybridized to 100 ng of target messenger RNA for varying lengths of time (21) . The excess probes were washed away using a magnetic-bead-based purification on the nCounter Prep station. Data collection and quantitative analysis of the codeset was carried out using the nCounter Digital Analyzer. The raw data were collected and normalized for the expression of included housekeeping genes. The analysis was then repeated on the 167 patient samples and 35 controls at less than 12 and 24 hours using the NanoString technology and compared for the 63 predictive genes with the previously reported microarray analysis (15) . Using the microarray data and the DFR (14), we then derived a metric that could be used to prospectively validate the genomic test.
Statistical Analysis
Continuous demographic variables were tested for normality, variance, and significance via one-way analysis of variance via Dunn or Tukey post-hoc analysis. Categorical demographic variables were tested for significance using a chi-square test. Separate univariate logistic regression models were fit to assess the association between DFR, Injury Severity Score (ISS), new Injury Severity Score (nISS), and Acute Physiology and Chronic Health Evaluation (APACHE II) scores as continuous independent measurements and outcome variable (complicated vs. uncomplicated clinical course). Receiver operating characteristic curve analysis was performed by calculating sensitivity and specificity for each independent variable. We constructed separate multivariable logistic models using clinical independent predictors only (ISS and APACHE II scores) or combining clinical predictors with genomic score (DFR in addition to ISS and APACHE II). All independent predictors were entered in each model as continuous variables. For each model, we performed model diagnostics to test for collinearity (using variance inflation factor and tolerance) and interactions. Model fit was evaluated using the Hosmer-Lemeshow goodness of fit test. Multiple receiver operating characteristic curve comparison analyses were performed to assess model predictive performance using area under the curve (AUC) for each model. AUC was used to assess model fit. AUC comparisons were made using ROCCONTRAST option available in LOGISTIC procedure using a nonparametric method that exploits the mathematical equivalence of the AUC to the Mann-Whitney U-statistic. All analyses were performed using SAS (v.9.2, Cary, NC) and SigmaStat v11 (Systat Software, San Jose, CA).
RESULTS
Genome-wide expression of whole blood leukocytes was determined at 12 hours, and 1, 4, 7, 14, and 28 days after severe blunt trauma in a cohort of 167 severe blunt trauma patients whose characteristics have been previously published (13) . Using clinical parameters, the 167 enrolled patients were divided into three cohorts based on their time to organ recovery, a new metric of organ failure recovery recently described by our group; it is defined as the time at which a patient is free from organ failure for at least 2 days. Prolonged time to organ recovery is associated with advanced age, increased severity of injury, To explore if there were differences in the genomic response to severe blunt trauma that may be associated with clinical recovery, we focused initially on the two extremes of the study population, those patients designated as having an uncomplicated clinical recovery versus those patients designated as having a complicated recovery. We found that there were 3,681 probe sets representing 2,435 genes whose expression over 28 days was significantly different between patients with an uncomplicated and complicated recovery, using a DFR adjusted probability of Q < 0.001. These genes were then filtered to include only those genes whose expression differed by at least twofold. A total of 63 significant genes were found to be different between patients with a complicated or uncomplicated recovery ( Fig. 1A and Table 3 ). Of the 63 genes whose expression was found to be significantly different between trauma patients with complicated and uncomplicated clinical recoveries, greater than two thirds were directly related to protective immunity. In fact, the greatest difference between complicated and uncomplicated patients was with the magnitude and duration of suppression of genes involved in adaptive immunity pathways, most notably the suppression of genes involved in antigen presentation (HLA-DQ, HLA-DR, HLA-DM, and CD74) and with interferon and interferoninducible genes (IFIT 1,2,3,5, IFI44, IFI44L, IFI6, OAS 1,2,3) . Next, we wanted to distill the expression values of these 63 genes to an easily understandable and clinically applicable, single metric. To do this, we utilized the DFR score, which we have previously shown to describe the overall genomic response of a patient compared with the response from a reference population-in this case, age-, gender-, and ethnicity-matched healthy controls. For each of the 96 patients classified as complicated or uncomplicated, we calculated a DFR score based on the expression level of the 63 genes over time ( Fig. 1B) (14) . The genomic response curves for these two patient populations diverge and separate by 24 hrs extending for at least 7 days; the differences in the genomic scores at less than 12 hours, 24 hours, and days 4 and 7 were statistically significant (p < 0.05 by Mann-Whitney rank analysis). The data suggest that a composite genomic score or DFR could be gener-ated to identify by 24 hours patients that will go on to experience an adverse outcome in response to trauma (Fig. 1B) .
Unfortunately, neither deep sequencing nor microarrays are amenable to a rapid turnaround time required for clinical decision making in the critically ill. In contrast, the NanoString nCounter multiplex array is a rapid (12-24 hr) assay that is capable of evaluating the expression of a large number of genes simultaneously (up to 800) for a patient and would offer a rapid turn-around alternative to microarray (21) . By modifying the quantities of starting material, we could further reduce the analytical time to a manageable 6-10 hours. To validate analytical variance; whether the NanoString technology could reproducibly generate similar gene expression patterns, we prospectively compared the NanoString quantitation of gene expression with the Affymetrix U133 + v2 GeneChip data using ex vivo LPS stimulation of whole human blood. Five replicates from a single sample of unstimulated or LPS-stimulated healthy, human whole blood were assessed for expression of the 63 genes identified above. As demonstrated in Figure 2A , both NanoString and microarray platform yielded similar results for the 63 genes, and were able to segregate samples based on whether or not the sample was stimulated with LPS. In addition, the expression of these 63 genes also correlated well between platforms (Fig. 2B , r = 0.88; (p < 0.0001), suggesting that the NanoString platform was as reproducible as microarray, and could offer a rapid turnaround alternative (6-10 hr) to lengthier microarray analyses, which can take upwards of 3-4 days. To further support and validate the NanoString platform in our trauma patient population, we evaluated the correlation of gene expression derived from both the microarray or NanoString platform of the 63 genes in the 167 trauma patients from samples taken at 24 hours after trauma. The expression of the 63 genes (Table 3) correlated well with an r value of 0.79 (p < 0.0001) ( Fig. 3) between both nanoString and microarray platforms, similar to the ex vivo LPS analyses. These data further support the capability of using a NanoString-based assay, in place of microarray, to rapidly identify the 63 genes within a trauma population. Next, we wanted to prospectively determine if a DFR score based on the NanoString platform obtained in the first 24 hours could be used to discriminate between patients that experienced adverse clinical recoveries versus those that did not. DFR scores were calculated for each patient at the 24-hour period, a time point that would have clinical relevance to the subsequent management of this population ( Fig. 1B) . Receiver-operator curves were then generated to determine the ability of the NanoString-based DFR to determine between either uncomplicated outcomes versus the other two groups, or complicated outcomes versus intermediate or .uncomplicated outcomes. Interestingly, NanoString-based DFR scores could differentiate those patients who would experience a complicated recovery from those who would go on to have either an uncomplicated or an intermediate recovery markedly better than seen with microarray. AUC value is 0.625 versus 0.811 for microarray versus nanoString, respectively, p = 0.0011 ( Fig. 4) . Surprisingly, the nanoString AUC values were also better than anatomic and physiologic predictors of clinical course and recovery, such as nISS, ISS, or APACHE II metrics ( Table 4) collected for these patients with p values of 0.005, 0.0009, and 0.0011, respectively ( Fig. 4) (14) . As shown in Figure 4 , addition of physiologic or anatomic scoring systems to the NanoString DFR resulted in only minimal and nonsignificant improvements in the AUC.
DISCUSSION
Multiple organ failure and sepsis remains a significant cause of posttraumatic injury morbidity and mortality (23, 24) . Identifying severely injured patients early who will have a complicated clinical outcome has been difficult and remains a significant clinical and therapeutic hurdle. Unfortunately, clinical trials for the treatment of patients with severe trauma or sepsis have been plagued by the inability to identify prospectively the patients who will or will not have a complicated recovery and might benefit from interventional therapies. Entry criteria are primarily physiologic and are limited to nonspecific inflammatory responses and overall organ injury, which may be too delayed to permit intervention to affect outcome. In addition, it is generally accepted that the well-established clinical criteria used to enter patients into severe trauma or sepsis clinical trials includes individuals who will either not benefit from the therapy or may actually be harmed (25) . Thus, being able to calculate a rapid (<24 hr) genomic score to exclude those patients who will recover and not require intervention, while identifying patients who will have a poor outcome, will be a useful tool for future clinical trials. Genome-wide expression analysis offers the advantage of surveying the entire transcriptome of a cell or tissue, and evaluating changes in expression without any preexisting bias. Past studies conducted by the Inflammation and Host Response to Injury Large Scale Collaborative Research Program (Glue Grant) have strongly suggested that information contained in the leukocyte transcriptome early after trauma could be used to discriminate much later clinical outcomes (14, 15) . Those studies identified families of genes involved in inflammation, antigen presentation, and T-cell responses as being discriminatory. Similarly, we were able to identify 63 genes whose expression was significantly different (DFR Q < 0.001 and fold change >2) between trauma patients with an uncomplicated and complicated outcome ( Table 3 and Fig. 1 ). ROC curves for comparison of multivariate analysis. Area under the curve for NanoString difference from reference is significantly higher than area under the curve for Injury Severity Score (ISS), new Injury Severity Score (nISS), and microarray models, with p = 0.005, 0.0009, and 0.0011, respectively. Adding NanoString difference from reference to Acute Physiology and Chronic Health Evaluation (APACHE) II and ISS model increases area under the curve significantly from 0.66 to 0.81 (p = 0.0026). Area under the curve for model with APACHE II, ISS, and NanoString difference from reference is significantly higher than area under the curve of the model with APACHE II, ISS, and microarray difference from reference (DFR) (p = 0.0008). Although a multiplex genomic approach to patient identification remains attractive, there are three technical challenges that must be overcome before a genomic test can be readily used in a critical care setting. First, there must be techniques that can readily and easily isolate the cell populations of interest from critically ill patients, in this case, total blood leukocytes. Second, microarray and sequencing approaches are both too time consuming and expensive to be used routinely and still suffer from a lack of clinical validation and reproducibility (26) . Third, genomic data must be reduced to a single metric that can be effectively interpreted and applied quickly. In severely traumatized or septic patients, this all must be accomplished within a matter of hours, not days or weeks.
We have successfully addressed all three issues. An alternative simpler and more rapid approach is the use of microfluidics chambers that lyse erythrocytes and yield a pure leukocyte population (27) . We have used these in the past in critically ill patients, and demonstrated that in 10 minutes, we can obtain yields of total leukocytes that give genomic signals comparable to that seen with macroscale techniques (28) . Second, the NanoString multiplex array was selected as an alternative to microarray because of its ability to rapidly assay for genomic expression, and when appropriately modified, can generate quantitative, reproducible results within 8-12 hours. In addition, because the hybridization technology does not require prior sample amplification, the messenger RNA concentration response curves should theoretically be more linear and result in less data compression than seen with microarrays. This increase in dynamic range offered by the NanoString platform may be one of the reasons why there is a difference in the discriminatory ability between the two platforms, as shown in Figure 4 . Regardless, we confirm that the genomic expression patterns for the 63 genes obtained by microarray correlate well with the expression values obtained by the using the NanoString platform both in vitro ( Fig. 2B ) and in vivo in the original 167 consortium patients who experienced severe blunt trauma ( Fig. 3) (13) . Finally, we used a genomic tool that consolidates all of the information in the 63 genes equally into a single metric (14) . Importantly, when the gene expression profile of each patient was distilled to a single genomic score, these scores were able to discriminate patients that developed a poor clinical outcome from those who recovered (Fig. 4) . Additionally, the calculated genomic score is a linear, normally distributed value in this cohort, and it would be very easy to reset the threshold to capture a less complicated clinical trajectory if one wished to do so. The precision of the assay decreases as the threshold is reduced, but it can be used to capture a larger at-risk population.
There are, however, a number of important considerations. First, this is a retrospective analysis and the genes were selected by identifying those whose expression differed over the 28-day study period. The DFR generated to predict clinical trajectory over the first 24 hours is therefore not independently obtained and must be validated prospectively before its value can be properly evaluated. Second, DFR scores are based on peripheral leukocyte expression from a relatively small cohort of 167 severely injured trauma patients without significant head injury. As a result, the ability to extend these results to other patient populations remains unknown. These caveats aside, the value and importance presented within this report rests with the ability to develop the infrastructure for integrating genomics into a rapid prognostic for the assessment of the critically ill patient.
It is generally accepted that earlier randomized controlled interventional trials have failed in this patient population in large part due to the heterogeneity of the patient population, as well as the inability to select the sickest patients with the highest mortality who have been shown to be the ones to ultimately benefit from therapy (25) . The clinical implications of this lie in the fact that this platform could ultimately be coupled to a therapeutic intervention that is aimed at the subset of patients predicted to have a complicated outcome, thus eliminating those expected to recover regardless of intervention.
Along the same lines, such a metric could actually be used to determine response to therapy. Of note, two-thirds (42) of the 63 genes identified as being differentially expressed between uncomplicated and complicated trauma patients are genes known to be associated with adaptive immunity in general, and specifically are known to be associated with interferon signaling. We found that the expression of these genes was suppressed in trauma patients with complicated outcomes. Such findings imply that this battery of genes might be useful in identifying not only patients at risk of complications after trauma, but also those who are responsive to biological response modifiers (29) . In this manner, the metric may be useful at identifying those patients who might benefit from therapies that target adaptive immunity such as interleukins 7 and 15, interferon gamma, and glucocorticoid-induced tumor necrosis factor receptor agonists, and also those patients who respond appropriately to the treatment modality.
Importantly, we describe the development of a novel rapid turnaround multiplex array that can be performed from blood sampling within a 12-to 18-hour time frame and integrated into a single metric or score that can predict long-term outcome and identify patients in whom interventional therapies may be beneficial. Though these findings will need to be validated in a larger multicenter trial, a multiplex DFR score based on the expression of the 63-gene subset has better discriminatory ability compared with other established clinical predictors based on organ failure or injury (Table 4 and Fig. 4 ). This would allow clinicians to identify patients who will be at risk for developing adverse clinical outcomes, thus allowing them to focus care on prevention of complications, such as secondary infections and multisystem organ failure.
